Skip to main content
. 2020 Nov 19;26(2):e218–e229. doi: 10.1002/onco.13576

Table 1.

Dose‐levels

Dose‐level hVEGF26‐104, μg RFASE, mg
Dose‐level 1 a 62.5 20
Dose‐level 2 125 20
Dose‐level 3A 250 20
Dose‐level 3B 250 40
Dose‐level 4 500 40
Dose‐level 5 1,000 40
a

The patients in dose‐level 1 received a first immunization with 20 mg RFASE alone to study the potential adverse effects of the adjuvant.

Abbreviation: RFASE, raffinose fatty acid sulphate ester.